NOVARTIS
CERTICAN® (everolimus)
0.1 mg, 0.25 mg dispersible tablets
Leaflet\

Name of the medicinal product

0.1 mg dispersible tablets
CERTICAN® 0.1 mg dispersible tablets

0.25 mg dispersible tablets
CERTICAN® 0.25 mg dispersible tablets

Qualitative and quantitative composition
The active substance is everolimus.

0.1 mg dispersible tablets
Each dispersible tablet contains 0.1 mg everolimus.                                            

0.25 mg dispersible tablets
Each dispersible tablet contains 0,25 mg everolimus.
For a fulI list of excipients, see section List of excipients.

Pharmaceutical formDispersible tablets are white to yellowish, marbled, round, flat with a bevelled edge
0.1 mg: engraved with "I" on one side and "NVR" on the other.
0.25 mg: engraved with "J0" on one side and "NVR" on the other.
Clinical particulars
 
Therapeutic indications
Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. Certican should be used in combination with ciclosporin for microemulsion and corticosteroids.

Posology and method of administrationTreatment with Certican should only be initiated and maintained by physicians who are experienced in immunosuppressive therapy following organ transplantation and who have access to everolimus whole blood levels monitoring.

Sumber : Badan POM RI